HCG Bengaluru pushes distress screening as ‘6th vital sign’ in cancer care

The initiative aligns with global psycho-oncology standards that advocate routine distress screening as a core quality benchmark in cancer treatment

Gilead to acquire Tubulis for up to $5 billion to strengthen its oncology portfolio

The acquisition complements Gilead’s existing oncology expertise and development infrastructure

Halozyme strikes global deal with Vertex to expand Hypercon drug delivery technology

The deal gives Vertex access to Halozyme’s Hypercon technology for up to three drug targets

RoosterBio taps MineBio to supercharge hMSC & exosome solutions in China

Stereotaxis bags FDA clearance for next-gen cath lab tech

Transgene and NEC join forces to advance personalized cancer vaccine

TG4050 harnesses Transgene’s myvac platform and NEC’s AI-powered neoantigen prediction technology to tailor vaccines to each patient’s tumor

Alpha Cognition secures key US patent for traumatic brain injury treatment

The patent, titled “ALPHA-1062 for treating Traumatic Brain Injury,” strengthens Alpha Cognition’s existing portfolio supporting both ALPHA-1062 and ZUNVEYL

OneCyte and Kemp Proteins to revolutionize cell line development

Biopharma companies face persistent hurdles in cell line development, including long timelines, low yields, and high failure rates for novel molecules

Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9 billion

The acquisition adds VYKAT XR (diazoxide choline), the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder, to Neurocrine’s portfolio

ImmunityBio responds to FDA concerns over promotional content